retatrutide thyroid cancer Schematic representation of hystotypes and their Thyroid Cancer Treatment (PDQ®) -

How Tirzepatide Compares Mechanistically to Semaglutide and Liraglutide | Feature | Tirzepatide | Semaglutide | Liraglutide | |---|---|---|---| | Receptor targets | GIP-R + GLP-1R | GLP-1R only | GLP-1R only | | Half-life | ~5 days | ~7 days | ~13 hours | | Dosing frequency | Weekly | Weekly | Daily | | Max approved weight loss dose | 15 mg | 2.4 mg (Wegovy) | 3 mg (Saxenda) | | Mean weight loss (key trial) | 20.9% (SURMOUNT-1) | 14.9% (STEP-1) | 5.8% (SCALE) | | Biased GLP-1R agonism | Yes (low beta-arrestin) | Partial | Lower | | Adipose GIPR mechanism | Yes | No | No | The 6-percentage-point gap in mean weight loss between tirzepatide and semaglutide in their respective Phase III key trials reflects the additive adipose and hypothalamic contributions of GIPR engagement [34]

Alhadeff AL, Rupprecht LE, Hayes MR (2012) GLP-1 neurons project to reward centers to control food intake.Endocrinology 153: 647-658

It also directly disposes of active oxygen forms with the help of the enzyme glutathione peroxidase

Arthritis Res Ther 2023